Skip to content
Companies

AcuraStem

Antisense drugs for ALS and frontotemporal dementia

Raised to date

No sales reported yet

of $5M offered across 1 Form D filing

Still open
$5M
Last filed
Jun 22, 2026

About

AcuraStem is a Pasadena, California biotechnology company developing antisense oligonucleotide therapeutics for neurodegenerative disease, principally ALS and frontotemporal dementia. Its iNeuroRx platform combines patient-derived neuron disease models with AI and bioinformatics to find targets, and produced the discovery of PIKFYVE as an ALS/FTD target published in Nature Medicine in 2018. Lead programs include PIKFYVE-targeting and UNC13A-targeting candidates, and the company licensed its PIKFYVE program to Takeda in a deal worth up to $580 million.

Targets are discovered in neurons derived from actual patients rather than animal models, which the company argues is why its candidates aim at sporadic ALS and FTD - the large majority of patients - instead of only the rare familial genetic subsets most ALS programs address.

Funding

  • Security to be acquiredFiled Jun 22, 2026Form D
    None sold/ $5M

Product

iNeuroRx

Drug discovery platform and therapeutics pipeline

A drug discovery platform that models neurodegenerative disease in patient-derived neurons and applies AI and bioinformatics to identify and validate therapeutic targets, then develops antisense oligonucleotide drugs against them.

  • Patient-derived neuron disease modeling
  • AI and bioinformatics target discovery
  • In-house antisense oligonucleotide (ASO) development expertise

Built for

Patients with ALS and frontotemporal dementia, reached via pharmaceutical partners who license and commercialize the programs

People on file